15188 Clinical responses by self-reported PsA status at baseline among patients with moderate to severe psoriasis treated with guselkumab versus secukinumab: Week 48 results from the ECLIPSE study

Abstract

Introduction: ECLIPSE, a phase 3 trial, compared guselkumab (GUS), an anti–interleukin-23 monoclonal antibody, to secukinumab (SEC), an anti–interleukin-17A monoclonal antibody for moderate to severe plaque psoriasis. Here, we evaluated consistency of responses of GUS vs SEC in subgroups of psoriasis patients with and without self-reported PsA.